Formation of a potential tumor therapeutic pharmaceutical 186Re-bleomycin

Formation of a potential tumor therapeutic pharmaceutical ¹⁸⁶Re-bleomycin

Luo Shun-Zhong，

Pu Man-Fei，

Qiao Jian，

Liu Guo-Ping，

Liu Zhong-Lin，

Zhao Peng-Ji，

Fu Yi-Bei，

Deng Hou-Fu

Nuclear Science and Techniques

Vol.9, No.1

pp.26-28

Published in print 01 Feb 1998

52900

The influence of experimental conditions on the formation of ¹⁸⁶Re-bleomycin (BLM) was studied. The results show that the labeling yield is mainly dependent on the pH value in reaction medium and gluconate can effectively protect the re-oxidation of Re reduced by Sn(II), A better method for preparing ¹⁸⁶Re-BLM is described with labeling yield up to 95% in the pH range from 3.0 to 4.5.

186Re-bleomycinTumor therapeutic agentSn(II) reducing methodGluconate protecting agent

References

Lillen D L, Jones S E, O' Mara R E et al. Cancer, 1973, 31: 903

Poulose K P, Watkins A E, Reba R C et al. J Nucl Med, 1975, 16: 839

Krohn K A, Meyers J, De Nardo G L.

Radiology, 1977, 122: 179

Hisada K, Ando A, Suzuki Y et al. Radioiso-topes, 1974, 23: 37

Yokoyama A, Terauchi Y, Horiuchi K et al. Int J Appl Radiat Isotopes, 1978, 29: 549

Korteland J, Dekker B G, De Ligny C L.

Int J Appl Radiat Isotopes, 1980, 31: 315

Luo Shun-Zhong, Liu Zhong-Lin, Zhang Chang-Ying et al. Journal of Isotopes (in Chinese), 1993, 6: 7